Activity
-
📣 PRESS RELEASE📣 This morning we are sharing some very exciting news from Adcendo! Today, we announce a licensing agreement with Multitude…
📣 PRESS RELEASE📣 This morning we are sharing some very exciting news from Adcendo! Today, we announce a licensing agreement with Multitude…
Liked by Paul Jackson
-
🚨🚨 MYRICX MEGAROUND! Congratulations to Robin Carr and team for raising a £90m ($114m) Series A to progress their pipeline of NMTi-based ADCs to…
🚨🚨 MYRICX MEGAROUND! Congratulations to Robin Carr and team for raising a £90m ($114m) Series A to progress their pipeline of NMTi-based ADCs to…
Liked by Paul Jackson
-
We are delighted to announce that Forbion has been recognized as the Top Performing European VC Manager as part of Preqin's 2024 Awards. This…
We are delighted to announce that Forbion has been recognized as the Top Performing European VC Manager as part of Preqin's 2024 Awards. This…
Liked by Paul Jackson
Experience
-
-
-
-
-
-
-
-
-
-
-
Education
-
King's College London
-
Thesis Title:
Development of In Silico Techniques for the Rational Design of Novel Pyrrolobenzodiazepine-Based Transcription Factor Inhibitors
More activity by Paul
-
Silk Road Medical announced it has entered into a definitive merger agreement to be acquired by Boston Scientific. The transaction has been…
Silk Road Medical announced it has entered into a definitive merger agreement to be acquired by Boston Scientific. The transaction has been…
Liked by Paul Jackson
-
Is Denmark closer to getting our own ‘Kendall Square’? Yes! Denmark has a lot to offer within the quantum and life science sectors. We have plenty…
Is Denmark closer to getting our own ‘Kendall Square’? Yes! Denmark has a lot to offer within the quantum and life science sectors. We have plenty…
Liked by Paul Jackson
-
📢📢NEW FUND! We are extremely happy to announce the first close of our new fund, Brandon Capital VI. The initial close is A$270m (US$180m) and will…
📢📢NEW FUND! We are extremely happy to announce the first close of our new fund, Brandon Capital VI. The initial close is A$270m (US$180m) and will…
Liked by Paul Jackson
-
Happy to share our most recent news of a new financing round in Adcendo. 😊
Happy to share our most recent news of a new financing round in Adcendo. 😊
Liked by Paul Jackson
-
📣 Pheon Therapeutics announces the closing of a $120m Series B financing to fund development of its differentiated #ADC pipeline!
📣 Pheon Therapeutics announces the closing of a $120m Series B financing to fund development of its differentiated #ADC pipeline!
Liked by Paul Jackson
-
Congratulations to Forbion portfolio company Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next…
Congratulations to Forbion portfolio company Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next…
Liked by Paul Jackson
-
This is such an exciting development! Brandon Capital's portfolio company Pheon's unique approach to #ADCs can have tremendous impact on patients…
This is such an exciting development! Brandon Capital's portfolio company Pheon's unique approach to #ADCs can have tremendous impact on patients…
Liked by Paul Jackson
-
🔔We are very happy to participate in the $120m Series B round for Pheon Therapeutics, who will use the proceeds to take their first in class ADC…
🔔We are very happy to participate in the $120m Series B round for Pheon Therapeutics, who will use the proceeds to take their first in class ADC…
Liked by Paul Jackson
-
Congratulations to the Pheon team! Well done on the fantastic progress made .
Congratulations to the Pheon team! Well done on the fantastic progress made .
Liked by Paul Jackson
-
Pheon Therapeutics is pleased to announce its CEO, Cyrus Mozayeni will be presenting at the LSX - partnering for Life Science eXecutives Inv€$tival…
Pheon Therapeutics is pleased to announce its CEO, Cyrus Mozayeni will be presenting at the LSX - partnering for Life Science eXecutives Inv€$tival…
Liked by Paul Jackson
-
Pheon Therapeutics is pleased to announce that it will be attending the 14th World ADC in San Diego on 16-19 October 2023. World ADC promises to be…
Pheon Therapeutics is pleased to announce that it will be attending the 14th World ADC in San Diego on 16-19 October 2023. World ADC promises to be…
Liked by Paul Jackson
-
We are pleased to announce the appointment of #oncology expert Arvin Yang, MD, PhD as Pheon Therapeutics Chief Medical Officer. Dr. Yang is a…
We are pleased to announce the appointment of #oncology expert Arvin Yang, MD, PhD as Pheon Therapeutics Chief Medical Officer. Dr. Yang is a…
Liked by Paul Jackson
-
Welcome to Jeff Albers on his appointment as Chairman of the Pheon Therapeutics Board of Directors. #PheonTherapeutics #ADCs #oncology…
Welcome to Jeff Albers on his appointment as Chairman of the Pheon Therapeutics Board of Directors. #PheonTherapeutics #ADCs #oncology…
Liked by Paul Jackson
-
Pheon Therapeutics is delighted to announce the appointment of industry veteran Cyrus Mozayeni as its new CEO. With an impressive track record…
Pheon Therapeutics is delighted to announce the appointment of industry veteran Cyrus Mozayeni as its new CEO. With an impressive track record…
Liked by Paul Jackson
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Paul Jackson in Ireland
-
Paul Jackson
Operations Manager TU Dublin
-
Paul Jackson
Operations Associate at Peppard Investments Ltd
-
Paul Jackson
Company Director
-
Paul Jackson
Seeking
12 others named Paul Jackson in Ireland are on LinkedIn
See others named Paul Jackson